A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Antifungal Agents; Caspofungin; Echinocandins; Miconazole

Criteria

Inclusion Criteria:

• Clinical and Laboratory evidence of blood stream &/or systemic candida infections

Exclusion Criteria:

• Possible candida contamination

• Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections

• Acute or moderately severe liver disease

• Abnormal liver function tests

• Abnormal blood clotting for patients on blood thinners